The following text is complete prescribing information based on official labeling in effect June 2000.

Bactrim (trimethoprim and sulfamethoxazole) is a synthetic antibacterial combination product available in DS (double strength) tablets, tablets and pediatric suspension for oral administration. Each DS tablet contains 160 mg trimethoprim and 800 mg sulfamethoxazole plus magnesium stearate, pregelatinized starch and sodium starch glycolate. Each tablet contains 80 mg trimethoprim and 400 mg sulfamethoxazole plus magnesium stearate, pregelatinized starch, sodium starch glycolate, FD&C Blue No. 1 lake, FD&C Yellow No. 6 lake and D&C Yellow No. 10 lake. Each teaspoonful (5 mL) of the pediatric suspension contains 40 mg trimethoprim and 200 mg sulfamethoxazole in a vehicle containing 0.3 percent alcohol, edetate disodium, glycerin, microcrystalline cellulose, parabens (methyl and propyl), polysorbate 80, saccharin sodium, simethicone, sorbitol, sucrose, FD&C Yellow No. 6, FD&C Red No. 40, flavors and water.

Trimethoprim is 2, 4-diamino-5-(3,4,5 trimethoxybenzyl)pyrimidine; the molecular formula is C 14 H 18 N 4 O 3 . It is a white to light yellow, odorless, bitter compound with a molecular weight of 290.3 and the following structural formula:

images/16/92003601.jpg

Sulfamethoxazole is N 1 -(5-methyl-3-isoxazolyl)sulfanilamide; the molecular formula is C 10 H 11 N 3 O 3 S. It is almost white, odorless, tasteless compound with a molecular weight of 253.28 and the following structural formula:

images/16/92003602.jpg

Bactrim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. The metabolism of sulfamethoxazole occurs predominately by N 4 -acetylation, although the glucuronide conjugate has been identified. The principal metabolites of trimethoprim are the 1- and 3-oxides and the 3'- and 4'- hydroxy derivatives. The free forms of sulfamethoxazole and trimethoprim are considered to be the therapeutically active forms. Approximately 44% of trimethoprim and 70% of sulfamethoxazole are bound to plasma proteins. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole.

Peak blood levels for the individual components occur 1 to 4 hours after oral administration. The mean serum half-lives of sulfamethoxazole and trimethoprim are 10 and 8 to 10 hours, respectively. However, patients with severely impaired renal function exhibit an increase in the half-lives of both components, requiring dosage regimen adjustment (see DOSAGE AND ADMINISTRATION section). Detectable amounts of trimethoprim and sulfamethoxazole are present in the blood 24 hours after drug administration. During administration of 160 mg trimethoprim and 800 mg sulfamethoxazole bid, the mean steady-state plasma concentration of trimethoprim was 1.72 µg/mL. The steady-state mean plasma levels of free and total sulfamethoxazole were 57.4 µg/mL and 68.0 µg/mL, respectively. These steady-state levels were achieved after three days of drug administration. 1

Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. The average percentage of the dose recovered in urine from 0 to 72 hours after a single oral dose of Bactrim is 84.5% for total sulfonamide and 66.8% for free trimethoprim. Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N 4 -acetylated metabolite. 2 When administered together as Bactrim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.

Both trimethoprim and sulfamethoxazole distribute to sputum, vaginal fluid and middle ear fluid; trimethoprim also distributes to bronchial secretion, and both pass the placental barrier and are excreted in human milk.

Microbiology:   Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para -aminobenzoic acid (PABA). Thus, trimethoprim and sulfamethoxazole block two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria.

In vitro studies have shown that bacterial resistance develops more slowly with both trimethoprim and sulfamethoxazole in combination than with either trimethoprim or sulfamethoxazole alone.

Trimethoprim and sulfamethoxazole have been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the section.

Aerobic gram-positive microorganisms:

Streptococcus pneumoniae

Aerobic gram-negative microorganisms:

Escherichia coli (including susceptible enterotoxigenic strains implicated in traveler's diarrhea)

Klebsiella species

Enterobacter species

Haemophilus influenzae

Morganella morganii

Proteus mirabilis

Proteus vulgaris

Shigella flexneri 3

Shigella sonnei 3

Other Organisms:

Pneumocystis carinii

Susceptibility Testing Methods:

Dilution Techniques:   Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method 4 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of trimethoprim/sulfamethoxazole powder. The MIC values should be interpreted according to the following criteria:

For testing Enterobacteriaceae:

MIC (µg/mL)
</= 2/38
Susceptible (S)
>/= 4/76
Resistant (R)

When testing either Haemophilus influenzae a or Streptococcus pneumoniae b :

MIC (µg/mL)
Interpretation b
</= 0.5/9.5
Susceptible (S)
1/19-2/38
>/= 4/76
Resistant (R)
a.These interpretative standards are applicable only to broth microdilution susceptibility tests with Haemophilus influenzae using Haemophilus Test Medium (HTM) 4 .
b.These interpretative standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2% to 5% lysed horse blood 4 .

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard trimethoprim/sulfamethoxazole powder should provide the following range of values:

MIC (µg/mL)
Escherichia coli
ATCC 25922
</= 0.5/9.5
Haemophilus influenzae c
ATCC 49247
0.03/0.59 - 0.25/4.75
Streptococcus pneumoniae d
ATCC 49619
0.12/2.4 - 1/19
c.This quality control range is applicable only to Haemophilus influenzae ATCC 49247 tested by broth microdilution procedure using Haemophilus Test Medium (HTM) 4 .
d.This quality control range is applicable to tests performed by the broth microdilution method only using cation-adjusted Mueller-Hinton broth with 2% to 5% lysed horse blood 4 .

Diffusion Techniques:

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure 5 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 1.25/23.75 µg of trimethoprim/sulfamethoxazole to test the susceptibility of microorganisms to trimethoprim/sulfamethoxazole.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 1.25/23.75 µg of trimethoprim/sulfamethoxazole disk should be interpreted according to the following criteria:

For testing either Enterobacteriaceae or Haemophilus influenzae e :

Zone Diameter (mm)
16
Susceptible (S)
11 - 15
10
Resistant (R)
e.These zone diameter standards are applicable only for disk diffusion testing with Haemophilus influenzae and Haemophilus Test Medium (HTM) 5 .

When testing Streptococcus pneumoniae f :

Zone Diameter (mm)
19
Susceptible (S)
16 - 18
15
Resistant (R)
f.These zone diameter interpretative standards are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood when incubated in 5% CO 2 5 .

Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for trimethoprim/sulfamethoxazole.

Quality Control

As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 1.25/23.75 µg trimethoprim/sulfamethoxazole disk * should provide the following zone diameters in these laboratory test quality control strains:

  Zone Diameter Ranges (mm)
Escherichia coli
ATCC 25922 24 - 32
Haemophilus influenzae g
ATCC 49247 24 - 32
Streptococcus pneumoniae h
ATCC 49619 20 - 28
* Mueller-Hinton agar should be checked for excessive levels of thymidine or thymine. To determine whether Mueller-Hinton medium has sufficiently low levels of thymidine and thymine, an Enterococcus faecalis (ATCC 29212 or ATCC 33186) may be tested with trimethoprim/sulfamethoxazole disks. A zone of inhibition >/= 20 mm that is essentially free of fine colonies indicates a sufficiently low level of thymidine and thymine.
g.This quality control range is applicable only to Haemophilus influenzae ATCC 49247 tested by a disk diffusion procedure using Haemophilus Test Medium (HTM) 5 .
h.This quality control range is applicable only to tests performed by disk diffusion using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood when incubated in 5% CO 2 5 .

Urinary Tract Infections:   For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species Enterobacter species Morganella morganii, Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.

Acute Otitis Media:   For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician Bactrim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of Bactrim in pediatric patients under two years of age. Bactrim is not indicated for prophylactic or prolonged administration in otitis media at any age.

Acute Exacerbations of Chronic Bronchitis in Adults:   For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician Bactrim offers some advantage over the use of a single antimicrobial agent.

Shigellosis:    For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated.

Pneumocystis Carinii Pneumonia:   For the treatment of documented Pneumocystis carinii pneumonia and for prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia

Traveler's Diarrhea in Adults:   For the treatment of traveler's diarrhea due to susceptible strains of enterotoxigenic E. coli .

CONTRAINDICATIONS

Bactrim is contraindicated in patients with a known hypersensitivity to trimethoprim or sulfonamides and in patients with documented megaloblastic anemia due to folate deficiency. Bactrim is also contraindicated in pregnant patients and nursing mothers, because sulfonamides pass the placenta and are excreted in the milk and may cause kernicterus. Bactrim is contraindicated in pediatric patients less than 2 months of age. Bactrim is also contraindicated in patients with marked hepatic damage or with severe renal insufficiency when renal function status cannot be monitored.

:   FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS.

SULFONAMIDES, INCLUDING SULFONAMIDE-CONTAINING PRODUCTS SUCH AS TRIMETHOPRIM/SULFAMETHOXAZOLE, SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR ANY SIGN OF ADVERSE REACTION. In rare instances, a skin rash may be followed by a more severe reaction, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, and serious blood disorders (see PRECAUTIONS ).

Clinical signs such as rash, sore throat, fever, arthralgia, pallor, purpura, or jaundice may be early indications of serious reactions.

Cough, shortness of breath, and pulmonary infiltrates are hypersensitivity reactions of the respiratory tract that have been reported in association with sulfonamide treatment.

The sulfonamides should not be used for the treatment of group A (beta)-hemolytic streptococcal infections. In an established infection, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as rheumatic fever.

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including trimethoprim/sulfamethoxazole, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of "antibiotic-associated colitis."

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug effective against C. difficile .

PRECAUTIONS

General:   Bactrim should be given with caution to patients with impaired renal or hepatic function, to those with possible folate deficiency (eg, the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with malabsorption syndrome, and patients in malnutrition states) and to those with severe allergies or bronchial asthma. In glucose-6-phosphate dehydrogenase deficient individuals, hemolysis may occur. This reaction is frequently dose-related (see and DOSAGE AND ADMINISTRATION ).

Cases of hypoglycemia in non-diabetic patients treated with Bactrim are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, malnutrition or those receiving high doses of Bactrim are particularly at risk.

Hematological changes indicative of folic acid deficiency may occur in elderly patients or in patients with preexisting folic acid deficiency or kidney failure. These effects are reversible by folinic acid therapy.

Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction.

As with all drugs containing sulfonamides, caution is advisable in patients with porphyria or thyroid dysfunction.

Use in the Elderly:   There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, eg, impaired kidney and/or liver function, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression (see and ADVERSE REACTIONS sections) or a specific decrease in platelets (with or without purpura) are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (see DOSAGE AND ADMINISTRATION section). The trimethoprim component of Bactrim may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency, or when given concomitantly with drugs known to induce hyperkalemia. Close monitoring of serum potassium is warranted in these patients. Discontinuation of Bactrim treatment is recommended to help lower potassium serum levels.

Use in the Treatment of and Prophylaxis for Pneumocystis Carinii Pneumonia in Patients with Acquired Immunodeficiency Syndrome (AIDS):   AIDS patients may not tolerate or respond to Bactrim in the same manner as non-AIDS patients. The incidence of side effects, particularly rash, fever, leukopenia and elevated aminotransferase (transaminase) values, with Bactrim therapy in AIDS patients who are being treated for Pneumocystis carinii pneumonia has been reported to be greatly increased compared with the incidence normally associated with the use of Bactrim in non-AIDS patients. The incidence of hyperkalemia appears to be increased in AIDS patients receiving Bactrim. Adverse effects are generally less severe in patients receiving Bactrim for prophylaxis. A history of mild intolerance to Bactrim in AIDS patients does not appear to predict intolerance of subsequent secondary prophylaxis. 6 However, if a patient develops skin rash or any sign of adverse reaction, therapy with Bactrim should be reevaluated (see ).

High dosage of trimethoprim, as used in patients with Pneumocystis carinii pneumonia, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause hyperkalemia when trimethoprim is administered to patients with underlying disorders of potassium metabolism, with renal insufficiency, or if drugs known to induce hyperkalemia are given concomitantly. Close monitoring of serum potassium is warranted in these patients.

During treatment, adequate fluid intake and urinary output should be ensured to prevent crystalluria. Patients who are "slow acetylators" may be more prone to idiosyncratic reactions to sulfonamides.

Information for Patients:   Patients should be instructed to maintain an adequate fluid intake in order to prevent crystalluria and stone formation.

Laboratory Tests:   Complete blood counts should be done frequently in patients receiving Bactrim; if a significant reduction in the count of any formed blood element is noted, Bactrim should be discontinued. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with impaired renal function.

Drug Interactions:   In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported.

It has been reported that Bactrim may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when Bactrim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.

Bactrim may inhibit the hepatic metabolism of phenytoin. Bactrim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.

Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations.

There have been reports of marked but reversible nephrotoxicity with coadministration of Bactrim and cyclosporine in renal transplant recipients.

Increased digoxin blood levels can occur with concomitant Bactrim therapy, especially in elderly patients. Serum digoxin levels should be monitored.

Increased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin.

Occasional reports suggest that patients receiving pyrimethamine as malaria prophylaxis in doses exceeding 25 mg weekly may develop megaloblastic anemia if Bactrim is prescribed.

The efficacy of tricyclic antidepressants can decrease when coadministered with Bactrim.

Like other sulfonamide-containing drugs, Bactrim potentiates the effect of oral hypoglycemics.

In the literature, a single case of toxic delirium has been reported after concomitant intake of trimethoprim/sulfamethoxazole and amantadine.

Drug/Laboratory Test Interactions:   Bactrim, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).

The presence of trimethoprim and sulfamethoxazole may also interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Carcinogenesis   Long-term studies in animals to evaluate carcinogenic potential have not been conducted with Bactrim.

Mutagenesis   Bacterial mutagenic studies have not been performed with sulfamethoxazole and trimethoprim in combination. Trimethoprim was demonstrated to be nonmutagenic in the Ames assay. No chromosomal damage was observed in human leukocytes cultured in vitro with sulfamethoxazole and trimethoprim alone or in combination; the concentrations used exceeded blood levels of these compounds following therapy with Bactrim. Observations of leukocytes obtained from patients treated with Bactrim revealed no chromosomal abnormalities.

Impairment of Fertility:   No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 70 mg/kg/day trimethoprim plus 350 mg/kg/day sulfamethoxazole. These doses are 10.9-fold higher than the recommended human dose for trimethoprim and sulfamethoxazole.

Pregnancy:   Teratogenic Effects: Pregnancy Category C. In rats, oral doses of 533 mg/kg sulfamethoxazole (16.7-fold higher than the recommended human dose) or 200 mg/kg trimethoprim (31.3-fold higher than the recommended human dose) produced teratologic effects manifested mainly as cleft palates.

The highest dose which did not cause cleft palates in rats was 512 mg/kg sulfamethoxazole (16-fold higher than the recommended human dose) or 192 mg/kg trimethoprim (30-fold higher than the recommended human dose) when administered separately. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole (16-fold higher than the recommended human dose) was used in combination with 128 mg/kg of trimethoprim (20-fold higher than the recommended human dose). In one study, however, cleft palates were observed in one litter out of 9 when 355 mg/kg of sulfamethoxazole (11.1-fold higher than the recommended human dose) was used in combination with 88 mg/kg of trimethoprim (13.8-fold higher than the recommended human dose).

In some rabbit studies, an overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with doses of trimethoprim 6 times the human therapeutic dose.

While there are no large, well-controlled studies on the use of trimethoprim and sulfamethoxazole in pregnant women, Brumfitt and Pursell, 7 in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or trimethoprim and sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim and sulfamethoxazole. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral trimethoprim and sulfamethoxazole at the time of conception or shortly thereafter.

Because trimethoprim and sulfamethoxazole may interfere with folic acid metabolism, Bactrim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects: See CONTRAINDICATIONS section.

Nursing Mothers:   See CONTRAINDICATIONS section.

Pediatric Use:   Bactrim is not recommended for pediatric patients younger than 2 months of age (see INDICATIONS and CONTRAINDICATIONS sections).

ADVERSE REACTIONS:   The most common adverse effects are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS (SEE SECTION

Hematologic:   Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic anemia, hypoprothrombinemia, methemoglobinemia, eosinophilia, pancytopenia, purpura.

Allergic Reactions:   Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schonlein purpura, serum sickness-like syndrome, generalized allergic reactions, generalized skin eruptions, photosensitivity, conjunctival and scleral injection, pruritus, urticaria and rash. In addition, periarteritis nodosa and systemic lupus erythematosus have been reported.

Gastrointestinal   Hepatitis (including cholestatic jaundice and hepatic necrosis), elevation of serum transaminase and bilirubin, pseudomembranous enterocolitis, pancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhea, anorexia.

Genitourinary:   Renal failure, interstitial nephritis, BUN and serum creatinine elevation, toxic nephrosis with oliguria and anuria, crystalluria and nephrotoxicity in association with cyclosporine.

Metabolic and Nutritional:   Hyperkalemia (see PRECAUTIONS : Use in the Elderly and Use in the Treatment of and Prophylaxis for Pneumocystis Carinii Pneumonia in Patients with Acquired Immunodeficiency Syndrome [AIDS] ).

Neurologic:   Aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache.

Psychiatric:   Hallucinations, depression, apathy, nervousness.

Endocrine:   The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. Diuresis and hypoglycemia have occurred rarely in patients receiving sulfonamides.

Musculoskeletal:   Arthralgia and myalgia. Isolated cases of rhabdomyolysis have been reported with Bactrim, mainly in AIDS patients.

Respiratory   Cough, shortness of breath, and pulmonary infiltrates (see ).

Miscellaneous:   Weakness, fatigue, insomnia.

OVERDOSAGE

Acute:   The amount of a single dose of Bactrim that is either associated with symptoms of overdosage or is likely to be life-threatening has not been reported. Signs and symptoms of overdosage reported with sulfonamides include anorexia, colic, nausea, vomiting, dizziness, headache, drowsiness and unconsciousness. Pyrexia, hematuria and crystalluria may be noted. Blood dyscrasias and jaundice are potential late manifestations of overdosage.

Signs of acute overdosage with trimethoprim include nausea, vomiting, dizziness, headache, mental depression, confusion and bone marrow depression.

General principles of treatment include the institution of gastric lavage or emesis, forcing oral fluids, and the administration of intravenous fluids if urine output is low and renal function is normal. Acidification of the urine will increase renal elimination of trimethoprim. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If a significant blood dyscrasia or jaundice occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating trimethoprim and sulfamethoxazole.

Chronic:   Use of Bactrim at high doses and/or for extended periods of time may cause bone marrow depression manifested as thrombocytopenia, leukopenia and/or megaloblastic anemia. If signs of bone marrow depression occur, the patient should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is restored.

DOSAGE AND ADMINISTRATION

Not recommended for use in pediatric patients less than 2 months of age.

Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Pediatric Patients:

Adults:   The usual adult dosage in the treatment of urinary tract infections is 1 Bactrim DS (double strength) tablet, 2 Bactrim tablets or 4 teaspoonfuls (20 mL) of Bactrim Pediatric Suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.

Pediatric Patients:   The recommended dose for pediatric patients with urinary tract infections or acute otitis media is 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage:

Pediatric Patients 2 months of age or older:

Weight Dose-every 12 hours
lb kg Teaspoonfuls Tablets
22 10 1 ( 5 mL) --
44 20 2 (10 mL) 1
66 30 3 (15 mL) 1 1 / 2
88 40 4 (20 mL) 2 or 1 DS tablet

For Patients with Impaired Renal Function:   When renal function is impaired, a reduced dosage should be employed using the following table:

Creatinine
Clearance (mL/min)
Recommended
Dosage Regimen
Above 30 Usual standard regimen
15-30 1 / 2 the usual regimen
Below 1 5 Use not recommended

Acute Exacerbations of Chronic Bronchitis in Adults:

The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 1 Bactrim DS (double strength) tablet, 2 Bactrim tablets or 4 teaspoonfuls (20 mL) of Bactrim Pediatric Suspension every 12 hours for 14 days.

Pneumocystis Carinii Pneumonia:

Treatment: Adults and Pediatric Patients:

The recommended dosage for treatment of patients with documented Pneumocystis carinii pneumonia is 15 to 20 mg/kg trimethoprim and 75 to 100 mg/kg sulfamethoxazole per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. 8 The following table is a guideline for the upper limit of this dosage.

Weight Dose-every 6 hours
lb kg Teaspoonfuls Tablets
18 8  1 ( 5 mL) --
35 16  2 (10 mL) 1
53 24  3 (15 mL) 1 1 / 2
70 32  4 (20 mL) 2 or 1 DS tablet
88 40  5 (25 mL) 2 1 / 2
106 48  6 (30 mL) 3 or 1 1 / 2 DS tablets
141 64  8 (40 mL) 4 or 2 DS tablets
176 80 10 (50 mL) 5 or 2 1 / 2 DS Tablets

For the lower limit dose (15 mg/kg trimethoprim and 75 mg/kg sulfamethoxazole per 24 hours) administer 75% of the dose in the above table.

Prophylaxis:

Adults:

The recommended dosage for prophylaxis in adults is 1 Bactrim DS (double strength) tablet daily. 9

Pediatric Patients:

For pediatric patients, the recommended dose is 150 mg/m 2 /day trimethoprim with 750 mg/m 2 /day sulfamethoxazole given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulfamethoxazole. 10 The following table is a guideline for the attainment of this dosage in pediatric patients:

Body Surface Area Dose-every 12 hours
(m 2 ) Teaspoonfuls Tablets
0.26 1 / 2  (2.5 mL) (2.5 mL) --
0.53 1  (5 mL) 1 / 2
1.06 2 (10 mL) 1

Traveler's Diarrhea in Adults:

For the treatment of traveler's diarrhea, the usual adult dosage is 1 Bactrim DS (double strength) tablet; 2 Bactrim tablets or 4 teaspoonfuls (20 mL) of Pediatric Suspension every 12 hours for 5 days.

HOW SUPPLIED

DS (double strength) Tablets  (white, notched, capsule shaped), containing 160 mg trimethoprim and 800 mg sulfamethoxazole--bottles of 100 (NDC 0004-0117-01), 250 (NDC 0004-0117-04) and 500 (NDC 0004-0117-14). Imprint on tablets: (front) BACTRIM-DS; (back) ROCHE.

Tablets  (light green, scored, capsule shaped), containing 80 mg trimethoprim and 400 mg sulfamethoxazole--bottles of 100 (NDC 0004-0050-01). Imprint on tablets: (front) BACTRIM; (back) ROCHE.

Pediatric Suspension  (pink, cherry flavored), containing 40 mg trimethoprim and 200 mg sulfamethoxazole per teaspoonful (5 mL)--bottles of 16 oz (1 pint) (NDC 0004-1033-28).

TABLETS SHOULD BE STORED AT 15° to 30°C (59° to 86°F) IN A DRY PLACE AND PROTECTED FROM LIGHT.

SUSPENSION SHOULD BE STORED AT 15° to 30°C (59° to 86°F) AND PROTECTED FROM LIGHT.

PRODUCT PHOTO(S):

NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug' identity should be verified by chemical analysis.

images/pills/p01332d0.jpg
images/pills/p01332d9.jpg

REFERENCES

  1. Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole in Man after Single and Repeated Doses. J Clin Pharmacol . Feb-Mar 1974; 14:112-117.
  2. Kaplan SA, et al. Pharmacokinetic Profile of Trimethoprim-Sulfamethoxazole in Man. J Infect Dis . Nov 1973; 128 (Suppl): S547-S555.
  3. Rudoy RC, Nelson JD, Haltalin KC. Antimicrobial Agents Chemother . May 1974;5:439-443.
  4. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ; Approved Standard--Fourth Edition. NCCLS Document M7-A4, Vol.17, No. 2, NCCLS, Wayne, PA, January, 1997.
  5. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests . Approved Standard--Sixth Edition. NCCLS Document M2-A6, Vol. 17, No. 1, NCCLS, Wayne, PA, January, 1997.
  6. Hardy DW, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immuno-deficiency syndrome. N Engl J Med . 1992; 327: 1842-1848.
  7. Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of Bacteriuria in Women. J Infect Dis . Nov 1973; 128 (Suppl):S657-S663.
  8. Masur H. Prevention and treatment of Pneumocystis pneumonia N Engl J Med . 1992; 327: 1853-1880.
  9. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodefficiency virus. MMWR . 1992; 41(RR-4):1-11.
  10. CDC Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR . 1991; 40(RR-2):1-13.

Rx only

Revised: July 2000